Sigyn Therapeutics, Inc. Stock Other OTC

Sigyn Therapeutics, Inc. develops medical devices to treat cancer and infectious disease disorders. The Company's lead therapeutic candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Candidate treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines. Its development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. Its ImmunePrep platform enhances the performance of immunotherapeutic antibodies.